Fabiola Cecchi, PharmD, PhD
Affiliations: | 2007-2012 | Urologic Oncology Branch | National Cancer Institue-NIH |
| 2013- | Astra-Zeneca (R&D) |
Google:
"Fabiola Cecchi"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Joseph Reilly | research assistant | 2009-2011 | National Cancer Institute |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cecchi F, Rex K, Schmidt J, et al. (2023) Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Cancers. 15 |
| Shah MA, Wainberg ZA, Catenacci DVT, et al. (2022) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 17: e0276211 |
| Shah MA, Wainberg ZA, Catenacci DVT, et al. (2021) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 16: e0261994 |
| Kummar S, Srivastava AK, Navas T, et al. (2021) Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs |
| Di Bartolomeo M, Raimondi A, Cecchi F, et al. (2020) Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori. 300891620930803 |
| Solocinski K, Padget MR, Fabian KP, et al. (2020) Overcoming hypoxia-induced functional suppression of NK cells. Journal For Immunotherapy of Cancer. 8 |
| Schaff LR, Yan D, Thyparambil S, et al. (2019) Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Journal of Neuro-Oncology |
| Serna G, Ruiz-Pace F, Cecchi F, et al. (2019) Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports. 9: 13568 |
| Toulmonde M, Pulido M, Ray-Coquard I, et al. (2019) Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. The Lancet. Oncology |
| Novoplansky O, Fury M, Prasad M, et al. (2019) MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International Journal of Cancer |